Mostrando 6 resultados de: 6
Filtros aplicados
Publisher
European Heart Journal(2)
American Journal of Clinical Nutrition(1)
BMJ Global Health(1)
Cardiovascular Diabetology(1)
Stroke(1)
Área temáticas
Enfermedades(5)
Fisiología humana(3)
Farmacología y terapéutica(2)
Medicina y salud(2)
Ginecología, obstetricia, pediatría, geriatría(1)
Association of nut intake with risk factors, cardiovascular disease, and mortality in 16 countries from 5 continents: Analysis from the Prospective Urban and Rural Epidemiology (PURE) study
ReviewAbstract: Background: The association of nuts with cardiovascular disease and deaths has been investigated mosPalabras claves:Cardiovascular disease, Global Health, Mortality , nuts, prospective cohortAutores:Ahmed S.H., Alhabib K.F., Altuntas Y., Amma L.I.K.R., Anand S.S., Bangdiwala S.I., Basiak-Rasała A., Dagenais G.R., De Souza R.J., Dehghan M., DIaz R., Ismail R., Kelishadi R., Khatib R., Lear S.A., Mente A., Mohan V., PATRICIO LOPEZ -JARAMILLO, Poirier P., Rangarajan S., Rosengren A., Swaminathan S., Teo K.K., Wentzel-Viljoen E., Yeates K.E., Yusuf R., Yusuf S.Fuentes:googlescopusAntihypertensives and Statin Therapy for Primary Stroke Prevention: A Secondary Analysis of the HOPE-3 Tria
ArticleAbstract: Background and Purpose: The HOPE-3 trial (Heart Outcomes Prevention Evaluation-3) found that antihypPalabras claves:Blood pressure, candesartan, Cardiovascular disease, Lipoprotein, Primary Prevention, statinAutores:Avezum A.J., Bosch J.J., Chazova I.E., Dagenais G.R., Gao P., Hart R.G., Held C., Khunti K., Leiter L.A., Lewis B.S., Lonn E.M., Pais P., PATRICIO LOPEZ -JARAMILLO, Peters R.J.G., Reid C.M., Sliwa K., Toff W.D., Yusoff K., Yusuf S., Zhu J.Fuentes:googlescopusLowering cholesterol, blood pressure, or both to prevent cardiovascular events: Results of 8.7 years of follow-up of Heart Outcomes Evaluation Prevention (HOPE)-3 study participants
ArticleAbstract: Aims: Rosuvastatin (10 mg per day) compared with placebo reduced major adverse cardiovascular (CV) ePalabras claves:Cardiovascular disease, Primary Prevention, statinsAutores:Avezum A.J., Bosch J.J., Dagenais G.R., Dans A.M., DIaz R., Held C., Jansky P., Joseph P.G., Jung H., Keltai K., Keltai M., Khunti K., Leiter L.A., Lewis B.S., Liu L., Lonn E.M., Pais P., Parkhomenko A.N., PATRICIO LOPEZ -JARAMILLO, Peters R.J.G., Piegas L.S., Reid C.M., Sliwa K., Toff W.D., Varigos J.D., Xavier D., Yusoff K., Yusuf S., Zhu J.Fuentes:googlescopusSimilar cardiovascular outcomes in patients with diabetes and established or high risk for coronary vascular disease treated with dulaglutide with and without baseline metformin
ArticleAbstract: Objective : Recent European Guidelines for Diabetes, Pbkp_rediabetes and Cardiovascular Diseases intPalabras claves:Cardiovascular disease, GLP-1-based therapy, Metformin, Morbidity, MortalityAutores:Avezum A.J., Basile J.N., Colhoun H.M., Cushman W.C., Dagenais G.R., DIaz R., Dyal L., Ferrannini G., Gerstein H.C., Jansky P., Keltai M., Lakshmanan M., Lanas F.T., Leiter L.A., Mellbin L., Pais P., PATRICIO LOPEZ -JARAMILLO, PīrCrossed D Sign gs V., Pogosova N., Probstfield J.L., Raubenheimer P.J., Riddle M.C., Rydén L.E., Shaw J.E., Sheu W.H.H.Fuentes:googlescopusThe household economic burden of non-communicable diseases in 18 countries
ArticleAbstract: Background Non-communicable diseases (NCDs) are the leading cause of death globally. In 2014, the UnPalabras claves:Cardiovascular disease, DIABÉTES, Health economics, health insurance, health systemsAutores:Alhabib K.F., Avezum A.J., Calik K.B.T., Chifamba J., Choudhury T., Dagenais G.R., Dans A.M., Gupta R., Hanson K., Iqbal R., Kaur M., Kelishadi R., Khatib R., Kruger L., Kutty V.R., Lear S.A., Li W., Mckee M., Mohan V., Mony P.K., Murphy A., Orlandini A., Palafox B., PATRICIO LOPEZ -JARAMILLO, Powell-Jackson T., Rangarajan S., Rosengren A., Rosnah I., Seron P., Teo K.K., Tse L.A., Tsolekile L.P., Walli-Attaei M., Wang Y., Wielgosz A., Yan R., Yeates K.E., Yusoff K., Yusuf S., Zatońska K.Fuentes:googlescopusTotal cardiovascular or fatal events in people with type 2 diabetes and cardiovascular risk factors treated with dulaglutide in the REWIND trail: a post hoc analysis
ArticleAbstract: Background: The Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) doublePalabras claves:Cardiovascular disease, Glucagon like peptide-1 receptor agonists, Type 2 DiabetesAutores:Atisso C.M., Basile J.N., Colhoun H.M., Conget I., Cushman W.C., Dagenais G.R., Dyal L., Gerstein H.C., Hall S., Keltai M., Lakshmanan M., Lanas F.T., Leiter L.A., Munoz E.G.C., Pais P., PATRICIO LOPEZ -JARAMILLO, Pirags V., Pogosova N., Probstfield J.L., Raubenheimer P.J., Riddle M.C., Rydén L.E., Shaw J.E., Sheu W.H.H., Temelkova-Kurktschiev T.Fuentes:googlescopus